Latest Liquidity News

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Jatcorp Limited reported a strong 36% revenue increase to $23 million for the half-year ended December 2025, narrowing its net loss and expanding its footprint across Asia Pacific markets despite ongoing legal challenges in China.

Gryphon Capital Income Trust reported a robust half-year profit increase alongside successful capital raises, positioning the fund for expanded investment in Australian RMBS and ABS markets.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

Duxton Farms Limited reported a significant half-year loss driven by acquisition and integration costs following a major portfolio expansion. The company is navigating a strategic shift towards diversified agriculture with plans to stabilise earnings over the coming years.

CVC Limited has finalized the unconditional sale of its Laverton property through a joint venture, forecasting a significant profit and strong cash inflow for FY 2026.

Norwood Systems has arranged a $200,000 working capital facility from a shareholder-related lender, aiming to support near-term liquidity and growth initiatives.

Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.

Neuren Pharmaceuticals reports a 15% rise in 2025 royalties from its partner Acadia’s DAYBUE sales, with strong 2026 guidance signalling further growth. The launch of a new powder formulation and ongoing regulatory efforts in Europe and Japan add to the momentum.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.